OLMAOlema Pharmaceuticals, Inc.Signing up patients
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Breast Cancer · Locally Advanced Breast Cancer · Metastatic Breast Cancer · ER Positive Breast Cancer · HER2 Negative Breast Carcinoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 1,000 (planned)
- Started
- Nov 3, 2025
- Main results expected
- Dec 2028
- Fully finished
- Jan 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-Free Survival (PFS)
Measured over: From Date of Randomization until Disease Progression or Death Due to Any Cause (estimated as up to 3.5 years)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07085767 · record last updated 2026-09-23 · checked 2026-11-09 15:47 UTC